

Jean M Mulcahy Levy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3842937/publications.pdf>

Version: 2024-02-01

59
papers

8,677
citations

361413

20
h-index

330143

37
g-index

62
all docs

62
docs citations

62
times ranked

18796
citing authors

#	ARTICLE	IF	CITATIONS
1	LGG-55. Autophagy sensitizes CNS tumors to targeted therapy by lowering their apoptotic threshold. <i>Neuro-Oncology</i> , 2022, 24, i101-i101.	1.2	1
2	OTHR-03. Oxaliplatin as a hearing-sparing alternative to carboplatin in tandem autologous stem cell transplants in pediatric CNS malignancy. <i>Neuro-Oncology</i> , 2022, 24, i147-i147.	1.2	1
3	EPID-06. Transfusion related iron overload in pediatric patients with CNS tumors. <i>Neuro-Oncology</i> , 2022, 24, i47-i48.	1.2	0
4	Medical and rehabilitation interventions in pediatric central nervous system radiation necrosis: A case report. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28705.	1.5	0
5	Deconvoluting Mechanisms of Acquired Resistance to RAF Inhibitors in BRAFV600E-Mutant Human Glioma. <i>Clinical Cancer Research</i> , 2021, 27, 6197-6208.	7.0	20
6	SARS-CoV-2 persistence in immunocompromised children. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29277.	1.5	11
7	Comprehensive molecular characterization of pediatric radiation-induced high-grade glioma. <i>Nature Communications</i> , 2021, 12, 5531.	12.8	31
8	491. Persistence of SARS-CoV-2 Infection in Immunocompromised Children. <i>Open Forum Infectious Diseases</i> , 2021, 8, S346-S347.	0.9	0
9	Targeted fusion analysis can aid in the classification and treatment of pediatric glioma, ependymoma, and glioneuronal tumors. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28028.	1.5	33
10	BPTF regulates growth of adult and pediatric high-grade glioma through the MYC pathway. <i>Oncogene</i> , 2020, 39, 2305-2327.	5.9	31
11	Autophagy in cancer: moving from understanding mechanism to improving therapy responses in patients. <i>Cell Death and Differentiation</i> , 2020, 27, 843-857.	11.2	278
12	Clinical and molecular characterization of a multi-institutional cohort of pediatric spinal cord low-grade gliomas. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa103.	0.7	6
13	Proteasome inhibition as a therapeutic approach in atypical teratoid/rhabdoid tumors. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa051.	0.7	8
14	ddPCR Analysis Reveals BRAF V600E Mutations Are Infrequent in Isolated Pituitary Langerhans Cell Histiocytosis Patients. <i>Journal of Neuropathology and Experimental Neurology</i> , 2020, 79, 1313-1319.	1.7	1
15	ETMR-22. TITLE: DEFINING THE CLINICAL AND PROGNOSTIC LANDSCAPE OF EMBRYONAL TUMORS WITH MULTI-LAYERED ROSETTES (ETMRs), A RARE BRAIN TUMOR REGISTRY (RBTC) STUDY. <i>Neuro-Oncology</i> , 2020, 22, iii327-iii328.	1.2	0
16	QOL-36. USE OF CANNABINOIDS IN THE PEDIATRIC CENTRAL NERVOUS SYSTEM TUMOR POPULATION. <i>Neuro-Oncology</i> , 2020, 22, iii438-iii438.	1.2	0
17	DDEL-06. DRUG INTERACTION BETWEEN EVEROLIMUS AND CANNABIDIOL IN PEDIATRIC PATIENTS WITH SUBEPENDYMAL GIANT CELL ASTROCYTOMAS: A SINGLE INSTITUTION EXPERIENCE. <i>Neuro-Oncology</i> , 2020, 22, iii284-iii284.	1.2	2
18	LGG-27. TARGETED THERAPY FOR PEDIATRIC LOW-GRADE GLIOMAS AND PLEXIFORM NEUROFIBROMAS WITH TRAMETINIB. <i>Neuro-Oncology</i> , 2020, 22, iii371-iii371.	1.2	0

#	ARTICLE	IF	CITATIONS
19	MEK inhibition with trametinib is a successful therapy in ganglioglioma. <i>Clinical Case Reports and Reviews</i> , 2020, 6, .	0.1	0
20	A C19MC-LIN28A-MYCN Oncogenic Circuit Driven by Hijacked Super-enhancers Is a Distinct Therapeutic Vulnerability in ETMRs: A Lethal Brain Tumor. <i>Cancer Cell</i> , 2019, 36, 51-67.e7.	16.8	69
21	Targeting IL-6 Is a Potential Treatment for Primary Cystic Craniopharyngioma. <i>Frontiers in Oncology</i> , 2019, 9, 791.	2.8	39
22	Effect of early-stage autophagy inhibition in BRAFV600E autophagy-dependent brain tumor cells. <i>Cell Death and Disease</i> , 2019, 10, 679.	6.3	24
23	EPEN-09. PRECLINICAL MODELS REVEAL SUBGROUP-STRATIFIED TARGETED THERAPY OPTIONS FOR CHILDHOOD SUPRATENTORIAL EPENDYMOMA. <i>Neuro-Oncology</i> , 2019, 21, ii79-ii79.	1.2	0
24	Safety and feasibility of outpatient autologous stem cell transplantation in pediatric patients with primary central nervous system tumors. <i>Bone Marrow Transplantation</i> , 2019, 54, 1605-1613.	2.4	7
25	LGG-16. PREDICTORS OF OUTCOME IN BRAF-V600E PEDIATRIC GLIOMAS TREATED WITH BRAF INHIBITORS: A REPORT FROM THE PLGG TASKFORCE. <i>Neuro-Oncology</i> , 2019, 21, ii102-ii102.	1.2	0
26	Preclinical analysis of MTOR complex 1/2 inhibition in diffuse intrinsic pontine glioma. <i>Oncology Reports</i> , 2018, 39, 455-464.	2.6	19
27	Specific expression of PD-1 in RELN-fusion supratentorial ependymoma: Implications for PD-1-targeted therapy. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26960.	1.5	44
28	Durable regression of Medulloblastoma after regional and intravenous delivery of anti-HER2 chimeric antigen receptor T cells. , 2018, 6, 30.		97
29	Improving Diagnostic and Therapeutic Outcomes in Pediatric Brain Tumors. <i>Molecular Diagnosis and Therapy</i> , 2018, 22, 25-39.	3.8	8
30	LGG-37. ASSESSMENT OF EARLY STAGE AUTOPHAGY INHIBITION IN BRAFV600E BRAIN TUMOR CELL RESPONSE TO CHEMOTHERAPY. <i>Neuro-Oncology</i> , 2018, 20, i112-i112.	1.2	0
31	DIPG-66. THE H3K27M MUTATION CAUSES WIDE-RANGING CHANGES MEDIATING DIPG TUMORIGENESIS. <i>Neuro-Oncology</i> , 2018, 20, i62-i62.	1.2	0
32	DIPG-77. INTRATUMORAL PHARMACOKINETICS OF CHEMOTHERAPY IN DIPG: XENOGRAFT AND INITIAL PHASE 0 CLINICAL TRIAL RESULTS. <i>Neuro-Oncology</i> , 2018, 20, i64-i65.	1.2	0
33	QOL-58. IMPROVEMENT IN VISUAL ACUITY OF PEDIATRIC PATIENTS WITH BRAIN TUMORS WITH BEVACIZUMAB. <i>Neuro-Oncology</i> , 2018, 20, i169-i169.	1.2	0
34	ATRT-18. VALIDATION OF PROTEASOME INHIBITION AS A THERAPEUTIC TARGET IN ATYPICAL TERATOID/RHABDOID TUMORS. <i>Neuro-Oncology</i> , 2018, 20, i31-i31.	1.2	0
35	QOL-52. USE OF CANNABINOIDS IN THE PEDIATRIC CENTRAL NERVOUS SYSTEM TUMOR POPULATION. <i>Neuro-Oncology</i> , 2018, 20, i168-i168.	1.2	2
36	TBIO-12. NON-TARGETED MUTATION AND FUSION ANALYSES CAN AID IN CLASSIFICATION AND TREATMENT OF PEDIATRIC GLIOMAS. <i>Neuro-Oncology</i> , 2018, 20, i182-i182.	1.2	0

#	ARTICLE	IF	CITATIONS
37	EPEN-14. SUBGROUP-SPECIFIC THERAPY OPTIONS FOR CHILDHOOD SUPRATENTORIAL EPENDYMOMA. <i>Neuro-Oncology</i> , 2018, 20, i76-i76.	1.2	0
38	Linking brain tumors and epileptic seizures. <i>Nature Medicine</i> , 2018, 24, 1638-1639.	30.7	3
39	LGG-59. REMARKABLE OBJECTIVE RESPONSE AND FAVORABLE SURVIVAL FOR BRAF-V600E CHILDHOOD LOW-GRADE GLIOMAS TO BRAF INHIBITORS COMPARED CONVENTIONAL CHEMOTHERAPY. <i>Neuro-Oncology</i> , 2018, 20, i117-i117.	1.2	0
40	Identification of FDA-Approved Oncology Drugs with Selective Potency in High-Risk Childhood Ependymoma. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1984-1994.	4.1	19
41	EPEN-15. RETINOIDS AS POTENTIAL CHEMOTHERAPEUTIC OPTIONS FOR POSTERIOR FOSSA EPENDYMOMA OF CHILDHOOD. <i>Neuro-Oncology</i> , 2018, 20, i76-i76.	1.2	0
42	Chordoma Occurs in Young Children With Tuberous Sclerosis. <i>Journal of Neuropathology and Experimental Neurology</i> , 2017, 76, 418-423.	1.7	10
43	Tumor treating fields in pediatric high-grade glioma. <i>Child's Nervous System</i> , 2017, 33, 1043-1045.	1.1	12
44	NF- κ B upregulation through epigenetic silencing of LDOC1 drives tumor biology and specific immunophenotype in Group A ependymoma. <i>Neuro-Oncology</i> , 2017, 19, 1350-1360.	1.2	32
45	Targeting autophagy in cancer. <i>Nature Reviews Cancer</i> , 2017, 17, 528-542.	28.4	1,856
46	Autophagy inhibition overcomes multiple mechanisms of resistance to BRAF inhibition in brain tumors. <i>ELife</i> , 2017, 6, .	6.0	128
47	Polo-like Kinase \hat{A} 1 as a potential therapeutic target in Diffuse Intrinsic Pontine Glioma. <i>BMC Cancer</i> , 2016, 16, 647.	2.6	31
48	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). <i>Autophagy</i> , 2016, 12, 1-222.	9.1	4,701
49	Checkpoint kinase 1 expression is an adverse prognostic marker and therapeutic target in MYC-driven medulloblastoma. <i>Oncotarget</i> , 2016, 7, 53881-53894.	1.8	17
50	Methylation-dependent loss of RIP3 expression in cancer represses programmed necrosis in response to chemotherapeutics. <i>Cell Research</i> , 2015, 25, 707-725.	12.0	354
51	EP-04 * ACTIVATION OF THE IL6/STAT3 PATHWAY IN CHILDHOOD EPENDYMOMA IS ASSOCIATED WITH A PRO-INFLAMMATORY TUMOR MICROENVIRONMENT AND A POOR PROGNOSIS. <i>Neuro-Oncology</i> , 2015, 17, iii6-iii6.	1.2	0
52	Interleukin-6/STAT3 Pathway Signaling Drives an Inflammatory Phenotype in Group A Ependymoma. <i>Cancer Immunology Research</i> , 2015, 3, 1165-1174.	3.4	61
53	STAT3-Mediated Autophagy Dependence Identifies Subtypes of Breast Cancer Where Autophagy Inhibition Can Be Efficacious. <i>Cancer Research</i> , 2014, 74, 2579-2590.	0.9	155
54	Using BRAF ^{V600E} as a marker of autophagy dependence in pediatric brain tumors. <i>Autophagy</i> , 2014, 10, 2077-2078.	9.1	18

#	ARTICLE	IF	CITATIONS
55	Pediatric Brainstem Gangliogliomas Show <i>BRAF^{V600E}</i> Mutation in a High Percentage of Cases. <i>Brain Pathology</i> , 2014, 24, 173-183.	4.1	52
56	Autophagy Inhibition Improves Chemosensitivity in BRAFV600E Brain Tumors. <i>Cancer Discovery</i> , 2014, 4, 773-780.	9.4	203
57	Late effects of total body irradiation and hematopoietic stem cell transplant in children under 3 years of age. <i>Pediatric Blood and Cancer</i> , 2013, 60, 700-704.	1.5	56
58	Modulation of pediatric brain tumor autophagy and chemosensitivity. <i>Journal of Neuro-Oncology</i> , 2012, 106, 281-290.	2.9	29
59	Targeting autophagy during cancer therapy to improve clinical outcomes. , 2011, 131, 130-141.		208